The latest NCCN guidelines [NCCN] suggest that completely resected IIB-IIIA (N1) NSCLC patients should undergo adjuvant systemic therapy with Osimertinib, if EGFR-mutated and after receiving standard adjuvant chemotherapy or if ineligible to receive platinum-based chemotherapy, or with Atezolizumab if PD-L1 ≥ 1%, EGFR and ALK are both the wild type, and standard adjuvant chemotherapy has been received. This evidence concerns the gene ALK and non-small cell lung carcinoma.